|
1
|
Sanjida S, Janda M, Kissane D, Shaw J,
Pearson SA, DiSipio T and Couper J: A systematic review and
meta-analysis of prescribing practices of antidepressants in cancer
patients. Psychooncology. 25:1002–1016. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Collet C, Schiltz C, Geoffroy V, Maroteaux
L, Launay JM and de Vernejoul MC: The serotonin 5-HT2B receptor
controls bone mass via osteoblast recruitment and proliferation.
FASEB J. 22:418–427. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Fanburg BL and Lee SL: A new role for an
old molecule: Serotonin as a mitogen. Am J Physiol. 272:L795–L806.
1997.PubMed/NCBI
|
|
4
|
Lesurtel M, Graf R, Aleil B, Walther DJ,
Tian Y, Jochum W, Gachet C, Bader M and Clavien PA:
Platelet-derived serotonin mediates liver regeneration. Science.
312:104–107. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Raymond JR, Mukhin YV, Gelasco A, Turner
J, Collinsworth G, Gettys TW, Grewal JS and Garnovskaya MN:
Multiplicity of mechanisms of serotonin receptor signal
transduction. Pharmacol Ther. 92:179–212. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Christensen DK, Armaiz-Pena GN, Ramirez E,
Matsuo K, Zimmerman B, Zand B, Shinn E, Goodheart MJ, Bender D,
Thaker PH, et al: SSRI use and clinical outcomes in epithelial
ovarian cancer. Oncotarget. 7:33179–33191. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Fatima S, Shi X, Lin Z, Chen GQ, Pan XH,
Wu JC, Ho JW, Lee NP, Gao H, Zhang G, et al: 5-Hydroxytryptamine
promotes hepatocellular carcinoma proliferation by influencing
β-catenin. Mol Oncol. 10:195–212. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gautam J, Bae YK and Kim JA: Up-regulation
of cathepsin S expression by HSP90 and 5-HT7 receptor-dependent
serotonin signaling correlates with triple negativity of human
breast cancer. Breast Cancer Res. 161:29–40. 2017. View Article : Google Scholar
|
|
9
|
Jiang SH, Li J, Dong FY, Yang JY, Liu DJ,
Yang XM, Wang YH, Yang MW, Fu XL, Zhang XX, et al: Increased
serotonin signaling contributes to the warburg effect in pancreatic
tumor cells under metabolic stress and promotes growth of
pancreatic tumors in mice. Gastroenterology. 153:277–291. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kubera M, Grygier B, Wrona D, Rogóż Z,
Roman A, Basta-Kaim A, Budziszewska B, Leskiewicz M, Jantas D,
Nowak W, et al: Stimulatory effect of antidepressant drug
pretreatment on progression of B16F10 melanoma in high-active male
and female C57BL/6J mice. J Neuroimmunol 240-241. 1–44. 2011.
|
|
11
|
Liang C, Chen W, Zhi X, Ma T, Xia X, Liu
H, Zhang Q, Hu Q, Zhang Y, Bai X and Liang T: Serotonin promotes
the proliferation of serum-deprived hepatocellular carcinoma cells
via upregulation of FOXO3a. Mol Cancer. 12:142013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Peters MA, Walenkamp AM, Kema IP, Meijer
C, de Vries EG and Oosting SF: Dopamine and serotonin regulate
tumor behavior by affecting angiogenesis. Drug Resist Updat.
17:96–104. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sarrouilhe D, Clarhaut J, Defamie N and
Mesnil M: Serotonin and cancer: What is the link? Curr Mol Med.
15:62–77. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Siddiqui EJ, Shabbir M, Mikhailidis DP,
Thompson CS and Mumtaz FH: The role of serotonin
(5-hydroxytryptamine1A and 1B) receptors in prostate cancer cell
proliferation. J Urol. 176:1648–1653. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Siddiqui EJ, Shabbir MA, Mikhailidis DP,
Mumtaz FH and Thompson CS: The effect of serotonin and serotonin
antagonists on bladder cancer cell proliferation. BJU Int.
97:634–639. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Siddiqui EJ, Thompson CS, Mikhailidis DP
and Mumtaz FH: The role of serotonin in tumour growth (review).
Oncol Rep. 14:1593–1597. 2005.PubMed/NCBI
|
|
17
|
Sui H, Xu H, Ji Q, Liu X, Zhou L, Song H,
Zhou X, Xu Y, Chen Z, Cai J, et al: 5-hydroxytryptamine receptor
(5-HT1DR) promotes colorectal cancer metastasis by regulating
Axin1/β-catenin/MMP-7 signaling pathway. Oncotarget. 6:25975–25987.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Vicaut E, Laemmel E and Stucker O: Impact
of serotonin on tumour growth. Ann Med. 32:187–194. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zong JC, Wang X, Zhou X, Wang C, Chen L,
Yin LJ, He BC and Deng ZL: Gut-derived serotonin induced by
depression promotes breast cancer bone metastasis through the
RUNX2/PTHrP/RANKL pathway in mice. Oncol Rep. 35:739–748. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Julius D, Huang KN, Livelli TJ, Axel R and
Jessell TM: The 5HT2 receptor defines a family of structurally
distinct but functionally conserved serotonin receptors. Proc Natl
Acad Sci USA. 87:928–932. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Julius D, Livelli TJ, Jessell TM and Axel
R: Ectopic expression of the serotonin 1c receptor and the
triggering of malignant transformation. Science. 244:1057–1062.
1989. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Jungwirth N, Haeberle L, Schrott KM,
Wullich B and Krause FS: Serotonin used as prognostic marker of
urological tumors. World J Urol. 26:499–504. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Dizeyi N, Bjartell A, Nilsson E, Hansson
J, Gadaleanu V, Cross N and Abrahamsson PA: Expression of serotonin
receptors and role of serotonin in human prostate cancer tissue and
cell lines. Prostate. 59:328–336. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Launay JM, Birraux G, Bondoux D, Callebert
J, Choi DS, Loric S and Maroteaux L: Ras involvement in signal
transduction by the serotonin 5-HT2B receptor. J Biol Chem.
271:3141–3147. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Dizeyi N, Bjartell A, Hedlund P, Tasken
KA, Gadaleanu V and Abrahamsson PA: Expression of serotonin
receptors 2B and 4 in human prostate cancer tissue and effects of
their antagonists on prostate cancer cell lines. Eur Urol.
47:895–900. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Dizeyi N, Hedlund P, Bjartell A, Tinzl M,
Austild-Tasken K and Abrahamsson PA: Serotonin activates MAP kinase
and PI3K/Akt signaling pathways in prostate cancer cell lines. Urol
Oncol. 29:436–445. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Barretina J, Caponigro G, Stransky N,
Venkatesan K, Margolin AA, Kim S, Wilson CJ, Lehár J, Kryukov GV,
Sonkin D, et al: The cancer cell line encyclopedia enables
predictive modelling of anticancer drug sensitivity. Nature.
483:603–607. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Modiano JF: Comparative pathogenesis of
cancers in animals and humans. Vet Sci. 3:2016.PubMed/NCBI
|
|
29
|
Stiles JM, Amaya C, Rains S, Diaz D, Pham
R, Battiste J, Modiano JF, Kokta V, Boucheron LE, Mitchell DC and
Bryan BA: Targeting of beta adrenergic receptors results in
therapeutic efficacy against models of hemangioendothelioma and
angiosarcoma. PLoS One. 8:e600212013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Spencer C, Montalvo J, McLaughlin SR and
Bryan BA: Small molecule inhibition of cytoskeletal dynamics in
melanoma tumors results in altered transcriptional expression
patterns of key genes involved in tumor initiation and progression.
Cancer Genomics Proteomics. 8:77–85. 2011.PubMed/NCBI
|
|
31
|
Gautam J, Banskota S, Regmi SC, Ahn S,
Jeon YH, Jeong H, Kim SJ, Nam TG, Jeong BS and Kim JA: Tryptophan
hydroxylase 1 and 5-HT7 receptor preferentially expressed in
triple-negative breast cancer promote cancer progression through
autocrine serotonin signaling. Mol Cancer. 15:752016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Gurbuz N, Asoglu MR, Ashour AA, Salama S,
Kilic GS and Ozpolat B: A selective serotonin 5-HT1B receptor
inhibition suppresses cells proliferation and induces apoptosis in
human uterine leiomyoma cells. Eur J Obstet Gynecol Reprod Biol.
206:114–119. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Gwynne WD, Hallett RM, Girgis-Gabardo A,
Bojovic B, Dvorkin-Gheva A, Aarts C, Dias K, Bane A and Hassell JA:
Serotonergic system antagonists target breast tumor initiating
cells and synergize with chemotherapy to shrink human breast tumor
xenografts. Oncotarget. 8:32101–32116. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Hejazi SH, Ahangari G and Deezagi A:
Alternative Viewpoint Against Breast Cancer Based on Selective
Serotonin Receptors 5HTR3A and 5HTR2A Antagonists that can Mediate
Apoptosis in MCF-7 Cell Line. Curr Drug Discov Technol. 12:240–249.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Abdel-Hamid NM, Shehata DE, Abdel-Ghany
AA, Ragaa A and Wahid A: Serum serotonin as unexpected potential
marker for staging of experimental hepatocellular carcinoma. Biomed
Pharmacother. 83:407–411. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kourtidis A, Lu R, Pence LJ and
Anastasiadis PZ: A central role for cadherin signaling in cancer.
Exp Cell Res. 358:78–85. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Leoncikas V, Wu H, Ward LT, Kierzek AM and
Plant NJ: Generation of 2,000 breast cancer metabolic landscapes
reveals a poor prognosis group with active serotonin production.
Sci Rep. 6:197712016. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Asada M, Ebihara S, Yamanda S, Niu K,
Okazaki T, Sora I and Arai H: Depletion of serotonin and selective
inhibition of 2B receptor suppressed tumor angiogenesis by
inhibiting endothelial nitric oxide synthase and extracellular
signal-regulated kinase 1/2 phosphorylation. Neoplasia. 11:408–417.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Banskota S, Gautam J, Regmi SC, Gurung P,
Park MH, Kim SJ, Nam TG, Jeong BS and Kim JA: BJ-1108, a
6-amino-2,4,5-trimethylpyridin-3-ol analog, inhibits
serotonin-induced angiogenesis and tumor growth through PI3K/NOX
pathway. PLoS One. 11:e01481332016. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Cattaneo MG, Palazzi E, Bondiolotti G and
Vicentini LM: 5-HT1D receptor type is involved in stimulation of
cell proliferation by serotonin in human small cell lung carcinoma.
Eur J Pharmacol. 268:425–430. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Ataee R, Ajdary S, Zarrindast M, Rezayat
M, Shokrgozar MA and Ataee A: Y25130 hydrochloride, a selective
5HT3 receptor antagonist has potent antimitogenic and apoptotic
effect on HT29 colorectal cancer cell line. Eur J Cancer Prev.
19:138–143. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Engel M, Smidt MP and van Hooft JA: The
serotonin 5-HT3 receptor: A novel neurodevelopmental target. Front
Cell Neurosci. 7:762013. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Cosgrove L, Shi L, Creasey DE,
Anaya-McKivergan M, Myers JA and Huybrechts KF: Antidepressants and
breast and ovarian cancer risk: A review of the literature and
researchers' financial associations with industry. PLoS One.
6:e182102011. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Chung CM, Kuo TM, Chiang SL, Wang ZH, Hung
CC, Lane HY, Liu CS and Ko YC: Antidepressants in association with
reducing risk of oral cancer occurrence: A nationwide
population-based cohort and nested case-control studies.
Oncotarget. 7:11687–11695. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Hsieh YH, Chiu WC, Lin CF, Chan HL, Liang
HY, Lee Y, McIntyre RS and Chen VC: Antidepressants and gastric
cancer: A nationwide population-based nested case-control study.
PLoS One. 10:e01436682015. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Chan HL, Hsieh YH, Lin CF, Liang HY, Huang
KY, Chiu WC, Lee Y, McIntyre RS and Chen VC: Invasive cervical
cancer and antidepressants: A nationwide population-based study.
Medicine. 94:e18662015. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Lee HC, Chiu WC, Wang TN, Liao YT, Chien
IC, Lee Y, McIntyre RS, Chen PC and Chen VC: Antidepressants and
colorectal cancer: A population-based nested case-control study. J
Affect Disord. 207:353–358. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Caudill JS, Brown PD, Cerhan JH and
Rummans TA: Selective serotonin reuptake inhibitors, glioblastoma
multiforme and impact on toxicities and overall survival: The mayo
clinic experience. Am J Clin Oncol. 34:385–387. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Pocha C, Knott A, Rector TS and Dieperink
E: Are selective serotonin reuptake inhibitors associated with
hepatocellular carcinoma in patients with hepatitis C? J Clin
Psychiatry. 75:e1122–e1126. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Boursi B, Lurie I, Haynes K, Mamtani R and
Yang YX: Chronic therapy with selective serotonin reuptake
inhibitors and survival in newly diagnosed cancer patients. Eur J
Cancer Care(Engl). 27:e126662018. View Article : Google Scholar
|
|
51
|
Boursi B, Lurie I, Mamtani R, Haynes K and
Yang YX: Anti-depressant therapy and cancer risk: A nested
case-control study. Eur Neuropsychopharmacol. 25:1147–1157. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Haukka J, Sankila R, Klaukka T, Lonnqvist
J, Niskanen L, Tanskanen A, Wahlbeck K and Tiihonen J: Incidence of
cancer and antidepressant medication: Record linkage study. Int J
Cancer. 126:285–296. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Xu W, Tamim H, Shapiro S, Stang MR and
Collet JP: Use of antidepressants and risk of colorectal cancer: A
nested case-control study. Lancet Oncol. 7:301–308. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Brandes LJ, Arron RJ, Bogdanovic RP, Tong
J, Zaborniak CL, Hogg GR, Warrington RC, Fang W and LaBella FS:
Stimulation of malignant growth in rodents by antidepressant drugs
at clinically relevant doses. Cancer Res. 52:3796–3800.
1992.PubMed/NCBI
|
|
55
|
Montoya A, Amaya CN, Belmont A, Diab N,
Trevino R, Villanueva G, Rains S, Sanchez LA, Badri N, Otoukesh S,
et al: Use of non-selective β-blockers is associated with decreased
tumor proliferative indices in early stage breast cancer.
Oncotarget. 8:6446–6460. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Thaker PH, Han LY, Kamat AA, Arevalo JM,
Takahashi R, Lu C, Jennings NB, Armaiz-Pena G, Bankson JA, Ravoori
M, et al: Chronic stress promotes tumor growth and angiogenesis in
a mouse model of ovarian carcinoma. Nat Med. 12:939–944. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Watkins JL, Thaker PH, Nick AM, Ramondetta
LM, Kumar S, Urbauer DL, Matsuo K, Squires KC, Coleman RL,
Lutgendorf SK, et al: Clinical impact of selective and nonselective
beta-blockers on survival in patients with ovarian cancer. Cancer.
121:3444–3451. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Leaute-Labreze C, Hoeger P,
Mazereeuw-Hautier J, Guibaud L, Baselga E, Posiunas G, Phillips RJ,
Caceres H, Lopez Gutierrez JC, Ballona R, et al: A randomized,
controlled trial of oral propranolol in infantile hemangioma. N
Engl J Med. 372:735–746. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Leaute-Labreze C and Taieb A: Efficacy of
beta-blockers in infantile capillary haemangiomas: The
physiopathological significance and therapeutic consequences. Ann
Dermatol Venereol. 135:860–862. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Banavali S, Pasquier E and Andre N:
Targeted therapy with propranolol and metronomic chemotherapy
combination: Sustained complete response of a relapsing metastatic
angiosarcoma. Ecancermedicalscience. 9:4992015. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Chow W, Amaya CN, Rains S, Chow M,
Dickerson EB and Bryan BA: Growth attenuation of cutaneous
angiosarcoma with propranolol-mediated β-blockade. JAMA Dermatol.
151:1226–1229. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Daguze J, Saint-Jean M, Peuvrel L,
Cassagnau E, Quéreux G, Khammari A and Dréno B: Visceral metastatic
angiosarcoma treated effectively with oral cyclophosphamide
combined with propranolol. JAAD Case Rep. 2:497–499. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Pasquier E, Andre N, Street J, Chougule A,
Rekhi B, Ghosh J, Philip DSJ, Meurer M, MacKenzie KL, Kavallaris M
and Banavali SD: Effective management of advanced angiosarcoma by
the synergistic combination of propranolol and vinblastine-based
metronomic chemotherapy: A bench to bedside study. EBioMedicine.
6:87–95. 2016. View Article : Google Scholar : PubMed/NCBI
|
